No abstract available.
Prostatic Hyperplasia*

No abstract available.
Prostatic Hyperplasia

No abstract available.
Prostatic Hyperplasia*

No abstract available.
Hyperplasia* ; Prostate* ; Prostatic Hyperplasia ; Prostatic Neoplasms

The study was made on 42 benign prostatic hyperplasia patients. The results showed that after one month therapy by traditional medication, symptoms scoring index IPSS reduced from 21.0 to 11.71 (p<0.05). The flow of urinary increased from 4.56ml/s to 8.98ml/s (p<0.05). Residual urine volume reduced from 16.52ml to 8.35ml (p<0.05). The therapeutic outcomes by the extract of "Than khi hoan gia giam" were classified as follows: Good in 23 cases (54.8%), Moderate in 15 cases (35.7%), Poor in 4 cases (9.5%).
Prostatic Hyperplasia ; Therapeutics ; Prostatic Hyperplasia ; Medicine, Traditional

No abstract available.
Prostatectomy* ; Prostatic Hyperplasia

No abstract available.
Laser Coagulation* ; Prostatic Hyperplasia*

No abstract available.
Apoptosis* ; Prostate* ; Prostatic Hyperplasia*

The literature has suggested that alpha-receptor blockade may have therapeutic value in treating the symptoms of patients with benign prostatic hypertrophy. Terazosin is an alpha-1 adrenergic blocking agent approved by the FDA for the treatment of benign prostatic hypertrophy. We treated 30 patients with symptomatic benign prostatic hypertrophy in double- blind fashion using terazosin and placebo. In placebo group, mean total symptom score was decreased from 9.8 to 7.7 (p <0.0001), but was statistically significant in only obstructive symptom score. Changes in maximal and mean urinary flow rates were from 9.8 to 10.3 and from 4.9 to 5.3, respectively, but there was no statistical significance (p>0.05). In terazosin group, the symptom score changes in obstructive and irritative were from 6.1 to 3.3 and from 4.5 to 5.9 (p <0.0001), respectively, and changes in maximal and mean urinary flow rates were from symptoms 8.7 to 10.2 and from 4.2 to 5.9, respectively (p<0.0001). There were significant improvements in all parameters in terazosin group when compared with placebo group (p<0.05). It was concluded that terazosin is beneficial for treatment of obstructive symptoms in patients with benign prostatic hypertrophy.
Humans ; Prostatic Hyperplasia*

Benign Prostate Hypertrophy (BPH) is often met in men of age 40 and over and its prevalence increases with age. 128 patients with BPH diagnosis have been included in study. Diagnosis has been based on: urinary disturbances scored by American Urinary Scale, rectal examination, volume measured by ultrasound exploration, serum PSA, post-surgical gland mass weighing and pathological evaluation. Results have shown: - There is linear relationship between 2 methods of gland mass definition with r= 0.736. Thus ultrasound method can be considered as good tool for gland mass definition.- 46.8% of BPH patients have PSA value in normal range but the rest of patients have elevated PSA value. With threshold of PSA at 15ng/ml value 120/128 patients have result above that threshold. This phenomena has relation with gland mass. The average volume of those with PSA< 5ng/ml is 40.1 cm3 but reached as high as 92.5cm3 on those with PSA>15ng/ml. This correlation is very close with r=0.458.
Prostatic Hyperplasia ; Antigens